



DFW

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85706

Osami HABUCHI, et al.

Appln. No.: 10/520,659

Group Art Unit: 1652

Confirmation No.: 5610

Examiner: Unknown

Filed: January 10, 2005

For: SULFOTRANSFERASE INHIBITOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/520,659

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,



Mark Boland
Registration No. 32,197


SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: April 7, 2006

Substitute for Form 1449 A & B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				<i>Complete if Known</i>	
				Application Number	10/520,659
				Confirmation Number	5610
				Filing Date	January 10, 2005
				First Named Inventor	Osami HABUCHI
				Art Unit	1652
				Examiner Name	Unknown
				Attorney Docket Number	Q85706
Sheet	1	of	1		

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
		US 6,365,365	B1	04/02/2002	Bistrup et al.
		US 6,265,192	B1	07/24/2001	Bistrup et al.
		US			
		US			
		US			
		US			
		US			
		US			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)			

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		Shiori Ohtake et al., "Human N-Acetylgalactosamine 4-Sulfate 6-O-Sulfotransferase cDNA Is Related to Human B Cell Recombination Activating Gene-associated Gene*" (2001), The Journal of Biological Chemistry, Vol. 276, No. 47, pp. 43894-43900	
		Lars Uhlin-Hansent et al., "Modulation of the Expression of Chondroitin Sulfate Proteoglycan in Stimulated Human Monocytes*" (1989), The Journal of Biological Chemistry, Vol. 264, No. 25, pp. 14916-14922	
		Glen L. Hortin et al., "INHIBITORS OF THE SULFATION OF PROTEINS, GLYCOPROTEINS, AND PROTEOGLYCANS" (1988), BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Vol. 150, No. 1, pp. 342-348	
		Geetha Sugumarant et al., "Effects of Brefeldin A on the Localization of Chondroitin Sulfatesynthesizing Enzymes" (1992), Vol. 267, No. 13, pp. 8802-8806	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.